Introduction {#s1}
============

Guanylyl cyclases (GCs) are a family of soluble and receptor-type enzymes that catalyze the conversion of GTP to cGMP (guanosine 3′,5′-cyclic monophosphate) in both vertebrates and invertebrates. GCs synthesize cGMP in response to signals, such as nitric oxide (NO), peptide ligands and changes in intracellular calcium ([@b14]; [@b27]; [@b32]; [@b38]). Intracellular cGMP regulates cellular events through cGMP-dependent protein kinases (cGKs), ion channels or phosphodiesterases, with cGKs representing the major intracellular effectors of cGMP signaling ([@b14]; [@b27]). The *Drosophila* genome encodes at least seven receptor and receptor-like GCs ([@b33]). *Drosophila* cGKs are encoded by two genes, *pkg21D* (*dg1*) and *foraging* (*for, dg2*). Some physiological functions of cGKs may be conserved between *Drosophila* and mammals. Both DG1 and DG2 modulate epithelial fluid transport by the Malpighian (renal) tubules ([@b28]) and mouse knock-outs of cGKII result in intestinal secretory defects ([@b40]). Although GCs and cGMP signaling are known to regulate multiple cellular and physiological events ([@b15]; [@b14]; [@b27]), their role in embryogenesis is poorly understood. In *Drosophila*, Guanylyl cyclase (Gyc) 32E is involved in oogenesis and in egg chamber development whereas Gyc76C is involved in axon guidance ([@b1]; [@b18]).

During embryogenesis adhesion of cells to one another and to the surrounding extracellular matrix (ECM) gives rise to three-dimensional tissues and organs. While some types of adhesions are stable, such as those between muscle and tendon cells, others, such as those between a migrating cell and the substratum upon which it migrates are transient. Cell-substratum adhesion is mediated by the integrin family of transmembrane adhesion receptors. Integrins exist as a heterodimer composed of a single α and a single β subunit that assemble into large intracellular protein complexes to regulate ECM binding and signaling to the cytoskeleton ([@b23]). In osteoclasts and pulmonary vascular smooth muscle cells cGKI plays a role in integrin-mediated adhesion ([@b36]; [@b54]). Specifically, in osteoclasts, cGK1 reorganizes αvβ3 integrin-mediated adhesion during cGMP-induced cell motility ([@b54]). Although these studies link cGMP signaling to integrin-mediated adhesion, whether cGMP signaling affects integrin-dependent adhesion in a developmental context is not known.

The *Drosophila* genome encodes two β integrin subunits and five α integrin subunits ([@b6]). During *Drosophila* embryogenesis, integrins are required for the migration of a number of cell types, such as cells of the primordial mid gut, salivary gland and trachea ([@b7]; [@b9]; [@b30]; [@b43]). Integrins are also required for the formation of stable adhesions, such as those at the MTJs, in humans ([@b21]) and in *Drosophila* ([@b12]). In *Drosophila*, growing myotubes elongate towards epidermal-derived tendon cells until they reach their respective tendon cells to form MTJs ([@b2]; [@b3]; [@b12]; [@b47]; [@b48]). In the absence of integrin function, the initial specification, fusion and attachment of muscle to tendon proceeds normally; however, muscles subsequently detach and round up ([@b8]; [@b11]; [@b29]; [@b37]; [@b42]). In this study, we report on a novel function for a receptor-type guanylyl cyclase, Gyc76C, and its downstream cGMP-dependent protein kinase, DG1, in *Drosophila* somatic muscle development, in particular, βPS integrin subunit localization at the developing MTJs.

Results {#s2}
=======

From a large-scale EMS mutagenesis screen, we identified several mutations affecting salivary gland and/or tracheal development ([@b34]). We previously reported that one of the mutations, *gimli^2388^,* affects tracheal branch migration ([@b34]). Through deficiency mapping, we identified the mutation in *gimli^2388^* as a novel allele of the receptor-type guanylyl cyclase at 76C (Gyc76C), hereafter referred to as *gyc76C^2388^* (see [Materials and Methods](#s4){ref-type="sec"} on mapping of *gyc76C^2388^*). The *gyc76C^2388^* mutation is a single nucleotide change of T to G in the 5′ end of the intron sequence following exon 16 changing the conserved GU at the splice donor site to GG. This nucleotide change results in the insertion of 92 intron base pair sequences from intron 6 which contains an in-frame stop codon before the guanylyl cyclase domain ([Fig. 1A](#f01){ref-type="fig"}). Thus, the Gyc76C protein produced in *gyc76C^2388^* mutant embryos likely lacks the cyclase domain.

![Molecular lesion of *gyc76C^2388^* and *gyc76C* RNA expression in the *Drosophila* embryo.\
A single nucleotide change from T to G in the 5′ intron sequence following exon 16 changes the conserved GU at the splice donor site to GG. This nucleotide change is followed by the insertion of 92 base pairs of intron 6 that contain an in-frame stop codon before the guanylyl cylcase domain (**A**). *gyc76C* RNA is expressed in the circular visceral mesoderm (CVM) (B, large arrow) overlying the migrating salivary gland (**B**, arrowhead) and in the fat body (FB) (B, small arrows) underlying the gland at stage 13, in the lateral body wall muscles (**C**, arrow) and in the tendon cells (**D**, arrow) at stage 15 and salivary gland (**E**, arrow) and midgut constrictions (**F**, arrow) at stage 16. *gyc76C* RNA is also expressed in the developing trachea (**G**) when primary branches such as the dorsal trunk (DT) are migrating out (G, arrow) at stage 12, when the DT undergoes anastomosis (**G**′) at stage 13 and is enriched apically in DT cells (**G**″) at stage 15. All embryos shown were processed for *in situ* hybridization to *gyc76C* RNA. Scale bar in B and G represents 20 µm.](bio-01-06-507-f01){#f01}

To understand *gyc76C* function in *Drosophila* embryogenesis, we analyzed the embryonic expression of *gyc76C* RNA. *Drosophila gyc76C* was previously shown to be expressed in the germarium during oogenesis and egg chamber development ([@b18]) and later in embryonic and adult tissues with a particular enrichment in the adult salivary glands ([@b13]; [@b26]; [@b31]). In mid-embryogenesis, *gyc76C* RNA was enriched in the circular visceral mesoderm (CVM) that overlies the migrating salivary gland and in the fat body (FB) that underlies the gland but at background levels in the gland itself ([Fig. 1B](#f01){ref-type="fig"}). In late embryogenesis, *gyc76C* RNA was detected in the mature salivary gland, in the somatic body wall muscles and the tendon cells to which the muscles attach, and in the constricting midgut ([Fig. 1C--F](#f01){ref-type="fig"}). *gyc76C* RNA was also expressed in the migrating tracheal cells at mid-embryogenesis and in the developed trachea at the end of embryogenesis with enrichment of the transcript in the apical domains ([Fig. 1G](#f01){ref-type="fig"}). Thus, the RNA expression pattern of *gyc76C* is consistent with the tracheal ([@b34]) and salivary gland (U.P. and M.M.M., unpublished) defects observed in *gyc76C^2388^* mutant embryos.

Gyc76C is required for somatic muscle development {#s2a}
-------------------------------------------------

Due to the prominent RNA expression of *gyc76C* in the somatic muscles, we investigated the role of *gyc76C* in embryonic somatic muscle development. The *Drosophila* somatic muscle consists of 30 mature muscles in each abdominal hemisegment that develop during mid- to late embryogenesis ([@b5]; [@b17]). *gyc76C^2388^* homozygous embryos showed an abnormal muscle pattern with numerous ventral and lateral muscles that failed to extend or were missing compared to heterozygous siblings ([Fig. 2A--D](#f02){ref-type="fig"}). Free unfused fusion competent myoblasts (FCMs) were present in some *gyc76C^2388^* homozygous embryos, suggesting a defect in myoblast fusion ([Fig. 2D](#f02){ref-type="fig"}). In contrast to the ventral and lateral muscles, dorsal muscles were largely unaffected by loss of *gyc76C* ([Fig. 2B,D](#f02){ref-type="fig"}). Scoring *gyc76C^2388^* heterozygous and homozygous embryos for gross patterning defects in the ventral and lateral muscles showed that although 60% of *gyc76C^2388^* homozygous embryos showed muscle defects at stage 15, only 20% showed defects by stage 16 indicating delayed muscle development ([Fig. 2K,L](#f02){ref-type="fig"}). We observed similar defects in embryos homozygous for *gyc76C^Ex173^*, an allele in which about 8 kb of genomic DNA including a *gyc76C* exon are deleted by imprecise P-element excision ([@b1]) and embryos *trans*-heterozygous for *gyc76C^2388^* and *gyc76C^Ex173^* ([Fig. 2E--H](#f02){ref-type="fig"}). To test whether the *gyc76C^2388^*allele is a null allele, we analyzed embryos *trans*-heterozygous for *gyc76C^2388^* and two overlapping deficiencies that delete the entire *gyc76C* gene, *Df(3L)fln1* and *Df(3L)XS533* ([Table 1](#t01){ref-type="table"}). We observed defects in somatic muscle patterning in embryos *trans*-heterozygous for *gyc76C^2388^*and either *Df(3L)fln1* or *Df(3L)XS533* to a similar severity as *gyc76C^2388^* homozygous embryos suggesting that *gyc76C^2388^* is either a null or a strong hypomorph allele ([Fig. 2I,J](#f02){ref-type="fig"}; data not shown).

![*Gyc76C* mutant embryos have defects in muscle development.\
In *gyc76C^238^*^8^ heterozygous embryos (**A**,**B**), ventral muscles (A,**A**′, arrows), lateral muscles (B, arrow) and dorsal muscles (B, arrowhead) are patterned normally. In *gyc76C^238^*^8^ homozygous embryos (**C**,**D**), ventral muscles (C,**C**′, arrows) and lateral muscles (D, arrowhead) are not patterned normally and unfused myoblasts are present (D, small arrow), whereas the dorsal muscles are patterned normally (D, arrow). In *gyc76C^Ex173^* homozygous embryos (**E**,**F**) and *trans*-heterozygous embryos of *gyc76C^2388^* and *gyc76C^Ex173^* (**G**,**H**), patterning of the ventral muscles (**E**′,**G**′, arrows) and lateral muscles (F,H, arrows) is abnormal, whereas the dorsal muscles (F, arrowhead) are patterned normally. In embryos *trans*-heterozygous for *gyc76C^238^*^8^and *Df* (*3L*) *XS533* (**I**,**J**), the ventral muscles (I,**I**′, arrows) and lateral muscles (J, arrow) are abnormally patterned. Graph depicting percentage of wild-type (WT), *gyc76C^2388^* and *gyc76C^Ex173^* mutant embryos and muscle-specific rescue embryos with patterning defects in the somatic muscle at stages 15 and 16 (**K**,**L**). Numbers indicate number of embryos scored. All embryos shown are at stage 16 and were stained for β3 tubulin (β3t) which labels all somatic muscles. Scale bars in A,A′ represent 20 µm.](bio-01-06-507-f02){#f02}

###### Deficiency lines used for mapping the *gimli^2388^* salivary gland migration defect.

![](bio-01-06-507-t01)

To test whether *gyc76C* acts cell-autonomously to regulate somatic muscle development, we expressed wild-type *gyc76C* (*gyc76C^WT^*) in the somatic and visceral muscle with *twi*-GAL4; *mef2*-GAL4. Muscle-specific expression of *gyc76C^WT^* in *gyc76C^2388^* homozygous embryos was sufficient to restore the normal pattern of the somatic body wall muscles such that only 10% of embryos showed muscle defects instead of 60% at stage 15 and only 5% of rescue embryos at stage 16 showed a patterning defect instead of 20% ([Fig. 2K,L](#f02){ref-type="fig"}). These data suggest that *gyc76C* function is required in the somatic muscle for proper patterning.

Loss of *pkg21D* phenocopies the *gyc76C* mutant muscle patterning phenotype {#s2b}
----------------------------------------------------------------------------

To determine whether the *Drosophila* cGMP-dependent kinases DG1 and DG2 were required for somatic muscle patterning, like *gyc76C*, we analyzed embryos mutant for *pkg21D* and *foraging* (*for*), encoding DG1 and DG2, respectively. We analyzed two viable hypomorph alleles of *pkg21D*, *pkg21D^f05504^* and *pkg21D^24228^*. In embryos mutant for either *pkg21D* allele, somatic muscles were patterned normally with mild defects in extension of the ventral oblique (VO) muscles ([Fig. 3B](#f03){ref-type="fig"}; data not shown). Similarly, in embryos *trans*-heterozygous for *gyc76C^2388^* and *pkg21D^f05504^,* somatic muscle patterning was largely intact and extension of the VO muscles was mildly affected ([Fig. 3C](#f03){ref-type="fig"}). To deplete the developing embryo of maternal and zygotic *pkg21D*, we expressed RNAi to *pkg21D* specifically in the muscle. We observed significantly more severe defects with DG1 knockdown in somatic muscle patterning with thinned VO and ventral acute (VA) muscles and the presence of FCMs, suggesting an earlier defect in myoblast fusion ([Fig. 3D](#f03){ref-type="fig"}). We did not detect muscle defects in embryos mutant for *for^12326^* or embryos expressing *for* RNAi specifically in the muscle (data not shown).

![DG1 regulates somatic muscle patterning and myotube extension with Gyc76C.\
In stage 16 wild-type embryos (**A**), VO (A, arrows) and VA (A, arrowheads) muscles extend towards the ventral midline. In *pkg21D^f05504^* mutant embryos (**B**) and embryos *trans*-heterozygous for *pkg21D^f05504^* and *gyc76C^2388^* (**C**), VO muscles are not as extended (B,C, arrows). In embryos expressing *pkg21D* RNAi specifically in the muscle with *twi*-GAL4; *mef2*-GAL4 (**D**), VO (D, large arrow) and VA (D, arrowheads) muscles are thinned and unfused myoblasts are present (D, small arrows). Embryos shown were stained for β3t which labels all somatic muscles as well as hemocytes (asterisks in D) in the vicinity. Scale bar in A represents 20 µm.](bio-01-06-507-f03){#f03}

Gyc76C and DG1 control integrin localization at the myotendinous junctions of dorsal muscles {#s2c}
--------------------------------------------------------------------------------------------

In contrast to the severe patterning defects observed for the ventral and lateral muscles in *gyc76C^2388^* and *pkg21D-*RNAi-treated embryos, the dorsal muscles of *gyc76C^2388^* and *gyc76C^Ex173^* homozygous embryos were largely intact with no unfused FCMS or gaps within the musculature ([Fig. 2D,F](#f02){ref-type="fig"}). Thus, we focused our analysis on the dorsal oblique 1 (DO1) and dorsal acute 1 (DA1) muscles to test whether *gyc76C* and *pkg21D* are required for proper formation of the myotendinous junctions (MTJs) which mediate attachment of muscles to their respective epidermal-derived tendon cells in an integrin-dependent manner. We first confirmed that specification and elongation of the dorsal muscles was not affected by loss of *gyc76C*. Staining for Kruppel which specifies the identity of several body wall muscles, including the DO and DA muscles ([Fig. 4A,B](#f04){ref-type="fig"}) ([@b44]) revealed that *gyc76C^2388^* homozygous embryos had a comparable number of DO1 and DA1 muscle nuclei to that of heterozygous siblings ([Fig. 4C,D](#f04){ref-type="fig"}). Moreover, staining for tropomyosin, which localizes to the cortex of all muscle cells, demonstrated that the DO1/DA1 muscles elongated towards the segment borders in *gyc76C^2388^* homozygous embryos as in heterozygous siblings ([Fig. 4E,F](#f04){ref-type="fig"}).

![Dorsal muscle specification and elongation are normal in *gyc76C* mutant embryos.\
(**A**,**B**) Schematic diagrams of somatic muscles highlighting the external dorsal oblique (DO) muscles (A,B, red) and the internal dorsal acute (DA) muscles (A,B, yellow). In *gyc76C^2388^* heterozygous and homozygous embryos (**C**,**D**), DO and DA muscles labeled with Kruppel (Kr) (**C**′,**D**′, white) are specified normally. In *gyc76C^2388^* heterozygous (**E**) and homozygous (**F**) embryos, DO and DA muscles elongate to span the entire length of the segment (E,F, arrows). Embryos in C,D were stained for Kr in white and β3t in green, whereas embryos in E,F were stained for Tropomyosin. All embryos were stained for β-galactosidase (β-gal) to distinguish heterozygous from homozygous embryos (not shown). Embryos in C,D are at stage 12 and those in E,F at stage 14. Diagrams in A,B were adapted from Beckett and Baylies, 2003. Scale bar in B represents 5 µm.](bio-01-06-507-f04){#f04}

Attachment of the body wall muscles to tendon cells at MTJs occurs in an integrin-dependent manner ([@b46]; [@b48]). In stage 16 *gyc76C^2388^* heterozygous embryos, the βPS integrin subunit was highly enriched at the MTJ of DO1/DA1 muscles with very little βPS present in the cytoplasm ([Fig. 5A](#f05){ref-type="fig"}). By contrast, in stage 16 *gyc76C^2388^* homozygous embryos, βPS at the MTJ was significantly reduced and its presence in the cytoplasm as discrete puncta was increased ([Fig. 5B](#f05){ref-type="fig"}). We quantified the change in βPS localization observed in *gyc76C^2388^* mutant embryos by measuring the fluorescent intensity ratio at the MTJs and in the cytoplasm (see [Materials and Methods](#s4){ref-type="sec"}). Our measurements showed that while wild-type and *gyc76C^2388^* heterozygous embryos showed a fluorescent intensity ratio between 5 and 6, *gyc76C^2388^* homozygous embryos showed a reduced ratio of approximately 3, suggesting reduced presence of βPS at the MTJ and/or increased presence in the cytoplasm ([Fig. 6](#f06){ref-type="fig"}). We observed similar defects in integrin localization in embryos homozygous for *gyc76C^Ex173^* ([Fig. 5C](#f05){ref-type="fig"}) and in embryos expressing RNAi to *gyc76C* specifically in the muscle ([Fig. 5D](#f05){ref-type="fig"}). In embryos expressing RNAi to *pkg21D*, βPS at the MTJ was similarly reduced and its presence as puncta in the cytoplasm of the DO1/DA1 muscles was increased ([Fig. 5E](#f05){ref-type="fig"}). Measurement of fluorescent intensity ratio demonstrated that inhibition of DG1 resulted in an almost equal distribution of βPS between the MTJ and cytoplasm ([Fig. 6](#f06){ref-type="fig"}). To determine whether *gyc76C* function was required in the muscle for proper localization of βPS at the MTJ, we expressed *gyc76C^WT^* in the muscle of *gyc76C^2388^*homozygous embryos. Expression of *gyc76C^WT^* in the muscle of *gyc76C^2388^*homozygous embryos rescued the βPS localization defect such that βPS was now enriched at the MTJ and continued to localize to intracellular puncta within the myotubes ([Fig. 5F](#f05){ref-type="fig"}).

![*gyc76C* and *pkg21D* control integrin localization at the MTJ.\
In *gyc76C^2388^* heterozygous embryos (**A**), βPS integrin (**A**′,**A**″, white) and F-actin (A, green) accumulate at MTJs (A″, arrow) and in intracellular puncta (A″, arrowhead). In embryos homozygous for *gyc76C^2388^* (**B**) or *gyc76C^Ex173^* (**C**), and embryos expressing RNAi to *gyc76C* (**D**) or *pkg21D* (**E**) specifically in the muscle with *twi*-GAL4; *mef2*-GAL4, βPS (**B**′--**E**′,**B**″--**E**″) is diffused at the MTJs (B″--E″, arrows) and is found as intracellular puncta in the dorsal muscles (B″--E″, arrowheads). In *gyc76C^2388^* homozygous embryos expressing *gyc76C^WT^* in the muscle with *twi*-GAL4; *mef2*GAL4 (F), βPS is enriched at the MTJs (**F**′,**F**″, arrow) and is also found as intracellular puncta (F,F″, arrowhead). All embryos were stained for βPS (white) and F-actin (green) with embryos in A--C,**F** being additionally stained for β-gal. Embryos in A-E are at stage 16 whereas the embryo in F is at stage 15. Scale bar in A and A″ represents 5 µm.](bio-01-06-507-f05){#f05}

![Quantification of βPS integrin levels at the MTJ.\
The ratio of fluorescent intensity at the MTJ and cytoplasm of DO1/DA1 muscles was measured for stage 16 wild-type embryos, *gyc76C^2388^* heterozygous and homozygous embryos and wild-type embryos expressing *pkg21D* RNAi in the muscle with *twi*-GAL4; *mef2*-GAL4. \*\*  = p\<0.001; \*\*\*  = p\<0.0001.](bio-01-06-507-f06){#f06}

We confirmed that reduced βPS localization at MTJs in *gyc76C^2388^* mutant embryos was not due to defects in specification or differentiation of tendon cells to which the dorsal muscles attach by staining for Stripe (Sr) and Held Out Wings (HOW) which label tendon cell precursors and differentiated tendon cells, respectively ([@b4]; [@b35]). In *gyc76C^2388^* heterozygous and homozygous embryos, staining for Sr and HOW showed a similar number of tendon cells ([Fig. 7A--D](#f07){ref-type="fig"}) demonstrating that the integrin localization defect observed in *gyc76C^2388^* mutant embryos was not due to a failure in tendon cell specification or differentiation.

![Tendon cell specification is normal in *gyc76C* mutant embryos.\
In *gyc76C^2388^* heterozygous (**A**,**C**) and homozygous (**B**,**D**) embryos, tendon cells are specified as indicated by Stripe (Sr) expression (A,**A**′,B,**B**′, red, arrows) and differentiate as indicated by HOW expression (C,**C**′,D,**D**′, red, arrows). Embryos in A,B were stained for Sr (red) and in C,D for HOW (red) and all embryos were co-stained for β3t to label dorsal muscles and β-gal to distinguish heterozygous from homozygous embryos (not shown). All embryos shown are at stage 16. Scale bar in A represents 5 µm.](bio-01-06-507-f07){#f07}

Discussion {#s3}
==========

In this study, we provide evidence for a novel role for Guanylyl cyclase at 76C (Gyc76C) in *Drosophila* somatic muscle development. We showed that *gyc76C* function is required in the somatic muscles for proper patterning and for localization of the βPS integrin subunit at the developing MTJs of the DO1/DA1 muscles. We also showed that the cGMP dependent protein kinase, DG1, is similarly required for muscle patterning and for integrin localization at the MTJ. The presence of unfused FCMs in *gyc76C^2388^* homozygous embryos and *pkg21D* RNAi-treated embryos suggests a role for cGMP signaling in early stages of muscle development, such as myoblast fusion. In addition to myoblast fusion, *gyc76C* may have a role in myotube extension since we observed shortened ventral muscles in *gyc76C* mutant embryos. It is likely that the maternal contribution of *gyc76C* in *gyc76C^2388^* mutant embryos allows sufficient patterning of the dorsal somatic muscles; however, it is not sufficient for proper localization of βPS integrin during MTJ formation. Therefore, our findings suggest that *gyc76C* and *pkg21D* regulate multiple stages of somatic muscle development.

Despite the significant role that integrins play in embryogenesis, little is known about how they are regulated. One mechanism for integrin control is through its turnover. It was first demonstrated in migrating mammalian cells that transient integrin-based adhesion to the ECM is achieved, at least in part, through the endocytosis and recycling of transmembrane integrins ([@b10]; [@b16]). More recently, it has been shown that integrin adhesion complexes at the *Drosophila* MTJ turnover in a clathrin- and Rab5-modulated process ([@b55]) and that integrin trafficking is regulated at least in part by phosphoinositides ([@b43a]). Our observation that loss of *gyc76C* or *pkg21D* promotes accumulation of βPS integrin subunit in intracellular puncta suggests a defect in integrin transport to the MTJ and/or its retention at the MTJ. Interestingly, previous reports have linked cGMP-dependent protein kinase I to integrin-mediated adhesion in osteoclasts and pulmonary vascular smooth muscle cells ([@b36]; [@b54]). Thus, guanylyl cylcases and downstream cGMP-signaling may play a conserved role in integrin mediated adhesion in multiple cell types.

cGMP signaling is known to play an important role in axon guidance ([@b50]; [@b49]). In the *Drosophila* embryo *gyc76C* is required for semaphorin-1a-plexin A-mediated repulsive guidance of motor axons ([@b1]). Although these studies showed that the cyclase activity of Gyc76C is important for axon repulsion, it is not known how signaling events downstream of Gyc76C directs the axonal response. Based on our studies, Gyc76C may regulate axon guidance by controlling integrin-mediated adhesion as it does in the muscle. In support of this, semaphorin-dependent control of cell migration is known to involve integrin-based adhesion ([@b39]; [@b51]; [@b52]; [@b56]).

Numerous studies identified a role for cGMP in cell migration and cytoskeletal remodeling. For example, elevation of cGMP levels disrupts actin stress fibers by cGK-dependent phosphorylation and inactivation of RhoA in vascular smooth muscle cells ([@b45]), and during chemotaxis of *Dictyostelium* amoebae, cGMP activates myosin light chain kinase to induce myosin filament formation and suppress pseudopod formation at the rear of the migrating cell ([@b19]). More recently, mammalian receptor type GC was shown to be activated in a phosphorylation-independent manner by p21-activiated kinase (Pak), a downstream effector of Rac GTPase, and this Rac-Pak-GC pathway is important for PDGF-induced lamellipodial formation and migration of cultured mammalian cells ([@b20]). cGMP-dependent protein kinase is also known to activate Rac1 and Pak1 ([@b22]), suggesting a positive feed-back loop for regulation of cell migration by the Rac-Pak-cGMP signaling pathway. Additional studies are necessary to determine whether Gyc76C regulates muscle development and specifically, integrin localization at the MTJs, through one or more of these signaling components.

Materials and Methods {#s4}
=====================

*Drosophila* strains and genetics {#s4a}
---------------------------------

Canton-S flies were used as wild-type controls. The following fly lines were obtained from the Bloomington Stock Center and are described in FlyBase (<http://flybase.bio.indiana.edu>): *Df(3L)fln1*, *Df(3L)XS533*, *Df(3L)e-19*, *Df(3L)kto2, Df(3L)ED4858, Df(3L)Exel9008, Df(3L)Exel9011, Df(3L)Exel9061, Df(3L)Exel9045*and *Df(3L)BSC1. gyc76C^2388^* was generated by standard EMS mutagenesis as previously described ([@b34]). PKG*^f05504^* was obtained from the Exelixis collection at Harvard Medical School and is described in FlyBase. *gyc76C^Ex173^* and UAS-*gyc76C^WT^* lines were gifts from A. Kolodkin (Johns Hopkins University School of Medicine, Baltimore, MD, USA). Generation of RNAi lines to *pkg21D*, *for* and *gyc76C* have been previously described ([@b38]; [@b53]). Expression of *pkg21D* RNAi and *gyc76C* RNAi in *Drosophila* Malpighian tubules resulted in an approximate knockdown of 30% and 40%, respectively (S.A.D., unpublished). UAS- *pkg21D* RNAi line was also obtained from the Vienna Drosophila RNAi Center (Vienna, Austria). Using the UAS-GAL4 expression system ([@b9a]), *mef2*-GAL4 and *twi*-GAL4 (gifts from M. Baylies \[Memorial Sloan-Kettering Cancer Institute, New York, NY USA\]) were used to drive muscle-specific expression of wild-type *gyc76C*.

Mapping of *gimli^2388^* mutation to *gyc76C* {#s4b}
---------------------------------------------

The *gimli^2388^* mutation was generated from a large scale EMS-mutagenesis screen for mutations affecting salivary gland and tracheal development ([@b34]). Complementation tests with 51 deficiency lines, which we previously reported to have salivary gland migration defects ([@b24]), identified two that failed to complement the lethality of *gimli^2388^*, *Df(3L)XS533* (deletes 76B04-77B) and *Df(3L)e-19* (deletes 93B06-93D2). Embryos homozygous for *Df(3L)XS533* or *Df(3L)e-19* showed defects in gland invagination and migration (data not shown). Moreover, embryos *trans*-heterozygous for *Df(3L)XS533* and *gimli^2388^* showed a gland phenotype identical to that of *Df(3L)XS533* homozygous embryos. Embryos *trans*-heterozygous for *gimli^2388^* and *Df(3L)e-19* did not show defects in gland development. Therefore, the *gimli^2388^* mutant chromosome has two lethal mutations, one that maps in the 76B04-77B region and another in the 93B06-93D2 region. However, the lethal mutation at 93 did not contribute to the gland migration defect of *gimli^2388^* and thus, the wild-type gene corresponding to *gimli^2388^* gene resided in the 76B04-77B genomic interval. We segregated these two independent mutations through meiotic recombination with the *rucuca* chromosome. We mapped the *gimli^2388^* mutation to a smaller interval within 76B04-77B by testing smaller overlapping deficiencies within these genomic regions for gland migration defects on their own and in*-trans* to *gimli^2388^* ([Table 1](#t01){ref-type="table"}). We identified one deficiency, *Df(3L)9061,* that deletes the 76C2-76C3 genomic region that showed a strong salivary galnd migration defect when homozygous and in *trans* to *gimli^2388^*. Bi-directional sequencing of the *gyc76C* gene in *gimli^2388^* mutant embryos revealed that the mutation in *gyc76C* is a single nucleotide change of T to G in the 5′ end of the intron sequence following exon 16 changing the conserved GU at the splice donor site to GG. This nucleotide change results in the insertion of 92 base pair sequences of intron 6 which contains an in-frame stop codon before the guanylyl cyclase domain.

Antibody staining of embryos {#s4c}
----------------------------

Embryo fixation and antibody staining were performed as previously described ([@b34]). The following antisera were used at the indicated dilutions: rabbit β3t antiserum (a gift from R. Renkawitz-Pohl, Philipps-University Marburg, Germany) at 1∶10,000; mouse βPS antiserum (Developmental Studies Hybridoma Bank, DSHB; Iowa City, IA) at 1∶200; rabbit Tropomyosin (abCAM, Cambridge, MA) at 1∶1000; rat Kruppel antiserum at 1∶40 (a gift from S. Small, New York University, NY, USA); guinea pig Stripe and rat HOW antisera (gifts from Talila Volk, Weizmann Institute, Rehovot, Israel) at 1∶200 and 1∶100, respectively and mouse β-galactosidase (β-gal) antiserum (Promega, Madison, WI) at 1∶10,000 for DAB staining and 1∶500 for fluorescence staining. Appropriate biotinylated- (Jackson Immunoresearch Laboratories, Westgrove, PA), AlexaFluor 488-, 647- or Rhodamine- (Molecular Probes, Eugene, OR) conjugated secondary antibodies were used at a dilution of 1∶500. Whole-mount DAB stained embryos were mounted in methyl salicylate (Sigma, St. Louis, MO) and embryos were visualized on a Zeiss Axioplan 2 microscope with Axiovision Rel 4.2 software (Carl Zeiss, Thornwood, NY). Whole-mount immunofluorescence stained embryos were mounted in Aqua Polymount (Polysciences, Inc., Warrington, PA) and thick (1 µm) fluorescence images were acquired on a Zeiss Axioplan microscope (Carl Zeiss) equipped with LSM 510 for laser scanning confocal microscopy at the Weill Cornell Medical College optical core facility (New York, NY).

RNA *in situ* hybridization {#s4d}
---------------------------

*In situ* hybridization (ISH) with antisense digoxigenin-labeled RNA probes for *gyc76C* was performed as previously described ([@b25]). *gyc76C* cDNA was obtained from Open Biosystems and was used as a template for generating antisense digoxygenin-labeled RNA probes as previously described. Embryos were mounted in 70% glycerol before visualization as described above for whole mount antibody staining.

Quantification of βPS fluorescence intensity {#s4e}
--------------------------------------------

Fluorescent intensity ratio between the MTJ and cytoplasm of the dorsal muscles was obtained using an established method ([@b41]). Specifically, Z-stack projections of approximately five 1-micron thick optical sections through the MTJ of DO1/DA1 muscles of at least seven representative embryos of each genotype immunolabeled with βPS and F-actin were selected for morphometric analysis. Three MTJs between abdominal segments 1 and 6 per embryo were selected for quantification. Fluorescent intensity within an area of approximately 2 µm^2^ (0.5×4) in the central region of the MTJ and a region of the exact size in the cytoplasm close to the MTJ of the DO1/DA1 muscle was measured using Image J software (National Institute of Health, Bethesda, MD) and its ratio (MTJ/Cyto) calculated. Identifical parameters were used for image acquisition and fluorescent intensity measurements in all genotypes analyzed. Statistical analysis was done using Microsoft Excel.
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